Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Implant or insert
Patent
1994-07-26
1998-01-06
Kishore, Gollamudi S.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Implant or insert
424423, 424426, 514 54, 514 59, 514 21, 514 2, A61F 1300, A61K 3800, A61K 31715
Patent
active
057051771
DESCRIPTION:
BRIEF SUMMARY
1. FIELD OF THE INVENTION
The present invention is directed to compositions comprising biocompatible anionic polymers and methods using such compositions to inhibit fibrosis, and attendant complications such as scar formation and surgical adhesions. Compositions and methods to inhibit glial cell invasion, neurite outgrowth and bone growth are also provided.
2. BACKGROUND OF THE INVENTION
Surgical adhesions--attachment of organs or tissues to each other through scar tissue--can produce clinical problems. The formation of scar tissue is a normal sequel to surgery or other tissue injury and is required for proper wound healing. In some cases, however, the scar tissue overgrows the intended region and creates surgical adhesions. These scar tissue surgical adhesions restrict the normal mobility and function of affected body parts. Where peripheral nerves are involved, fibrous adhesions can elicit severe pain during normal movement. Furthermore scars and keloid tissue (raised scar tissue) are often unsightly and present psychological and emotional problems.
2.1. Peridural Fibrosis
A clinically important example of detrimental scar formation occurs with peridural fibrosis. This condition leads to recurrent low back pain after lumbar laminectomy and diskectomy (Cauchoix et al., 1978, Spine 3: 256-259; Jackson, 1971, J. Bone Joint Surg. 53B: 409-616; Pheasant, 1985, Orthop. Clin. North Am. 6: 319-329; Yong-Hing et al., 1980, Spine 5: 59-64). Tissue scar formation restricts nerve root mobility and has been correlated with recurrent radicular pain, often in the same distribution as the previously herniated disk (Benoist, M. et al., 1980, Spine 5: 432-436).
2.2. Prevention of Detrimental Scarring
A number of workers have studied the effectiveness of various treatments for preventing peridural fibrosis. Fat grafts have been used with some success to prevent or ameliorate scar formation (LaRocca and Macnab, 1974, J. Bone Joint Surg. 56B: 545-550; Langenskold and Kivilvoto, 1976, Clin. Orthrop. 115: 82-85; Gill et al., 1985, Spine 10: 662-667; Gill et al., 1979, Spine 4: 176-185; Yong-Hing et al., 1980, Spine 5: 59-64). Gelfoam (denatured collagen gel) and silastic membranes showed some effectiveness in preventing adhesions (LaRocca and Macnab, supra); later studies, however, indicated that gelfoam was ineffective or promoted scar formation (Gill, 1985 supra; Gill, 1979, supra; Yong-Hing, supra). Songer et al. reported that sodium hyaluronate, but not gelfoam or anterior fat grafts, retarded fibrosis and reduced fibroblast invasion in a dog model (1990, Spine 15: 550-554).
2.3. Cell Invasion and Attachment
Previous work by Snow et al., (1990, Exp. Neurol. 309: 111-130) demonstrated that keratan sulfate/chrondroitin sulfate-proteoglycan (KS/CS-PG) is inhibitory to neurite outgrowth from embryonic (E-9) chick dorsal root ganglia (DRGs). Neurites either stopped abruptly or turned and travelled along the KS/CS-PG stripe border. This phenomenon was dependent upon the concentration of the proteoglycan, with intermediate concentrations producing intermittent patterns of crossing.
A number of studies have considered the role of proteoglycans in cell attachment. Unfractionated cartilage proteoglycans, and to a lesser extent a purified cartilage component, chondroitin sulfate, were found to inhibit fibroblast binding to collagen and fibronectin in vitro (Rich, et al., 1981, Nature 293: 224-226). Dermatan sulfate proteoglycan (DS-PG) was observed to inhibit the attachment and spreading of 3T3 fibroblasts on plasma fibronectin-coated culture substrata (Lewandowska et al., 1987, J. Cell Biol. 105: 1443-1454; Rosenberg, L. C. et al., 1986, CIBA Foundation Symposium 124: 47-68). Dextran sulfate and high molecular weight heparin decreased the initial rate of attachment of chinese hamster ovary and G-8 mouse myoblast cells to collagen (Klebe, R. J. and P. J. Mock, 1982, J. Cell. Physiol. 112: 5-9). Proteoglycan isolated from cartilage, freed from glycoproteins and hyaluronic acid, retards attachment of a variety of cell type
REFERENCES:
patent: 2715091 (1955-08-01), Ricketts et al.
patent: 3487150 (1969-12-01), Barnes et al.
patent: 3627872 (1971-12-01), Parkinson
patent: 3632754 (1972-01-01), Balassa
patent: 3847155 (1974-11-01), Bernaola
patent: 3886947 (1975-06-01), Sawyer
patent: 3914413 (1975-10-01), Balassa
patent: 4021544 (1977-05-01), Nair et al.
patent: 4066829 (1978-01-01), Nair et al.
patent: 4141973 (1979-02-01), Balazs
patent: 4207312 (1980-06-01), Fujii et al.
patent: 4225580 (1980-09-01), Rothman et al.
patent: 4232007 (1980-11-01), Kajihara et al.
patent: 4271084 (1981-06-01), Ishikawa et al.
patent: 4280954 (1981-07-01), Yannas et al.
patent: 4315002 (1982-02-01), Maurer
patent: 4321273 (1982-03-01), Ishikawa et al.
patent: 4350629 (1982-09-01), Yannas et al.
patent: 4428939 (1984-01-01), Prockop
patent: 4448718 (1984-05-01), Yannas et al.
patent: 4465666 (1984-08-01), Lukas et al.
patent: 4485088 (1984-11-01), Chvapil
patent: 4496397 (1985-01-01), Waite
patent: 4536496 (1985-08-01), Shimizu et al.
patent: 4537767 (1985-08-01), Rothman et al.
patent: 4538603 (1985-09-01), Pawelchak et al.
patent: 4585585 (1986-04-01), Waite
patent: 4592864 (1986-06-01), Miyata et al.
patent: 4609640 (1986-09-01), Morishita et al.
patent: 4613502 (1986-09-01), Turkova et al.
patent: 4618490 (1986-10-01), De Marco
patent: 4625016 (1986-11-01), Prockop
patent: 4640912 (1987-02-01), Hausman
patent: 4659572 (1987-04-01), Murray
patent: 4672031 (1987-06-01), Prockop
patent: 4687740 (1987-08-01), Waite
patent: 4692435 (1987-09-01), Lormeau et al.
patent: 4703108 (1987-10-01), Silver et al.
patent: 4710493 (1987-12-01), Landsberger
patent: 4713446 (1987-12-01), DeVore et al.
patent: 4716224 (1987-12-01), Sakurai et al.
patent: 4728642 (1988-03-01), Pawelchak et al.
patent: 4745098 (1988-05-01), Michaeli
patent: 4747848 (1988-05-01), Maini
patent: 4755379 (1988-07-01), Jozefonvicz et al.
patent: 4760131 (1988-07-01), Sundsmo et al.
patent: 4773408 (1988-09-01), Cilento et al.
patent: 4773409 (1988-09-01), Cilento et al.
patent: 4778768 (1988-10-01), Heinegard et al.
patent: 4783447 (1988-11-01), Del Bono et al.
patent: 4788200 (1988-11-01), Niwa et al.
patent: 4793336 (1988-12-01), Wang
patent: 4801619 (1989-01-01), Lindblad
patent: 4803075 (1989-02-01), Wallace et al.
patent: 4804652 (1989-02-01), Lormeau et al.
patent: 4808570 (1989-02-01), Michaeli
patent: 4820303 (1989-04-01), Brauman
patent: 4829000 (1989-05-01), Kleinman et al.
patent: 4837024 (1989-06-01), Michaeli
patent: 4840941 (1989-06-01), Ueno et al.
patent: 4863907 (1989-09-01), Sakurai et al.
patent: 4865846 (1989-09-01), Kaufman
patent: 4880429 (1989-11-01), Stone
patent: 4882148 (1989-11-01), Pinchuk
patent: 4886787 (1989-12-01), de Belder et al.
patent: 4908350 (1990-03-01), Kramer et al.
patent: 4912093 (1990-03-01), Michaeli
patent: 4925678 (1990-05-01), Ranney
patent: 4925924 (1990-05-01), Silver et al.
patent: 4927806 (1990-05-01), Kramer et al.
patent: 4943630 (1990-07-01), Jacquinet et al.
patent: 4945086 (1990-07-01), Benitz et al.
patent: 4992533 (1991-02-01), Kobayashi et al.
patent: 5008253 (1991-04-01), Casu et al.
patent: 5013724 (1991-05-01), Petitou et al.
patent: 5015677 (1991-05-01), Benedict et al.
patent: 5049403 (1991-09-01), Larm et al.
patent: 5055301 (1991-10-01), Voigt et al.
patent: 5089479 (1992-02-01), Krivan et al.
patent: 5108759 (1992-04-01), Ranney
patent: 5112608 (1992-05-01), Scott et al.
patent: 5120322 (1992-06-01), Davis et al.
patent: 5126440 (1992-06-01), Paris et al.
patent: 5135920 (1992-08-01), Kanamaru et al.
patent: 5152978 (1992-10-01), Baba et al.
patent: 5153181 (1992-10-01), Diringer et al.
patent: 5196185 (1993-03-01), Silver et al.
patent: 5196196 (1993-03-01), Scott et al.
patent: 5213898 (1993-05-01), Larm et al.
patent: 5227372 (1993-07-01), Folkman
Abrams, et al., 1989, Oral Dextran Sulfate (UAO01) In The Treatment Of The Acquired Immunodeficiency Syndrome (AIDS) and AIDS-Related Complex, Annuals Int. Med., 110: 183-188.
Adler, 1988, Inhibition Of Rat Glomerular Visc
Coker, III George T.
Frederickson Robert C. A.
Harel Adrian
Roufa Dikla
Gliatech Inc.
Kishore Gollamudi S.
LandOfFree
Methods and compositions based on inhibition of cell invasion an does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions based on inhibition of cell invasion an, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions based on inhibition of cell invasion an will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2326668